Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepindolol is a small molecule beta blocker of the indole class, structurally described as a 2-methyl derivative of pindolol. It acts primarily as a selective beta1-adrenoreceptor antagonist with intrinsic sympathomimetic activity (ISA), meaning it can partially mimic the effects of catecholamines while blocking their action. This results in decreased heart rate and blood pressure, making it useful for managing cardiovascular conditions such as hypertension and angina pectoris. Additionally, mepindolol has been investigated for its ability to lower intraocular pressure in glaucoma by reducing aqueous humor production through antagonism of beta receptors in the ciliary body. The drug does not significantly affect lipid levels; total plasma cholesterol may decrease while HDL-cholesterol increases during therapy[1][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mepindolol.